Study Sponsor: Vaccinex Pharmaceuticals

Phase: Phase II, Safety and Efficacy

Clinical Sites in NC: Duke, Wake Forest


SIGNALThe SIGNAL trial is designed to assess the safety, tolerability, and effectiveness of VX15, a novel monoclonal antibody in people with late prodromal or early manifest Huntington’s disease (HD). This is a different class of drug than any other drug used in previous HD clinical trials. Monoclonal antibodies are more specific than most other drugs because